CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage.

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Short interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...